Clinical Trial Update: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors [EARLY_Phase 1]

View source ↗

Summary

Early-phase safety study of the radiopharmaceutical 212Pb-VMT-alpha-NET in patients with neuroendocrine tumors is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor
• Pulmonary Neuroendocrine Tumor

Drugs mentioned

• [212Pb]VMT-alpha-NET (212Pb-VMT-alpha-NET)

Snippet

Sponsor: David Bushnell | Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING